第四剂COVID-19 BNT162b2 mRNA疫苗(第二剂加强针)的安全性:一项前瞻性与回顾性队列研究
为评估第二剂BNT162b2 mRNA COVID-19加强针的安全性,研究分析以色列Maccabi Healthcare Services 25万随机成员中94169名接种第一剂加强针者和17814名接种第二剂加强针者的回顾性队列,以及全以色列4698名参与者的前瞻性PerMed队列。回顾性分析比较接种前后各42天25种潜在不良事件的风险差异,第二剂加强针与所查25种不良事件均无关联,包括心肌梗死(风险差2.25例/万人,95%CI -3.93至8.98)和贝尔麻痹(-1.68例,-5.61至2.25),接种后无人诊断心肌炎或心包炎。前瞻性队列中第一剂与第二剂加强针接种后心率(第2天p=0.3,第6天p=0.89)及自报反应程度(p=0.06)无显著差异;第二剂加强针后前3天平均心率较基线显著升高(p<0.0001),第2天达峰(平均差1.61次/分,1.07至2.16),第6天回到基线(-0.055次/分,-0.56至0.45)。作者认为该研究为符合条件人群提供安全性保证。
要点
- 回顾性队列中第二剂加强针与所查25种不良事件均无关联,心肌梗死风险差2.25例/万人(95%CI -3.93至8.98),贝尔麻痹-1.68例(-5.61至2.25)。
- 接种第二剂加强针后无人诊断心肌炎或心包炎。
- 前瞻性队列第一剂与第二剂加强针后心率(第2天p=0.3,第6天p=0.89)及自报反应程度(p=0.06)无显著差异。
- 第二剂加强针后前3天平均心率较基线显著升高(p<0.0001),第2天达峰,平均差1.61次/分(1.07至2.16)。
- 第二剂加强针后第6天平均心率回到基线,与基线差-0.055次/分(-0.56至0.45)。
适用人群与场景
- 回顾性队列:年龄18岁及以上、在2021年12月30日至2022年7月22日接种活动期间接种第二剂BNT162b2 mRNA COVID-19加强针者,来自以色列第二大卫生机构Maccabi Healthcare Services的25万随机成员。
- 前瞻性PerMed队列:年龄18岁及以上、入组时为Maccabi Healthcare Services成员、使用本人智能手机并能自行签署知情同意者,来自以色列全国各地。
研究设计与关键结果
- 回顾性队列:94169人接种第一剂加强针,17814人接种第二剂加强针;比较接种前后各42天,第二剂加强针与所查25种潜在不良事件均无关联。
- 心肌梗死风险差2.25例/万人(95%CI -3.93至8.98),贝尔麻痹风险差-1.68例/万人(95%CI -5.61至2.25);接种第二剂加强针后无人诊断心肌炎或心包炎。
- 前瞻性队列:1785人接种第一剂加强针,699人接种第二剂加强针;第一剂与第二剂加强针接种后无显著差异(心率:第2天p=0.3,第6天p=0.89;自报反应程度p=0.06)。
- 第二剂加强针后前3天平均心率较接种前一周(基线)显著升高(p<0.0001),第2天达峰,平均差1.61次/分(95%CI 1.07至2.16)。
- 第二剂加强针后第6天平均心率回到基线,与基线差-0.055次/分(95%CI -0.56至0.45)。
证据类型、等级与局限
- 证据类型:前瞻性队列(PerMed研究)与回顾性队列。
对床旁实践的改变
- 作者认为,回顾性与前瞻性分析均支持第二剂加强针的安全性,研究结果反映了医生诊断、患者客观生理指标和患者主观反应。
- 作者认为,该研究为全球符合条件接种额外COVID-19加强针的人群提供安全性保证,有助于增加选择接种该加强针的高危人群数量,从而预防COVID-19相关重症结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effectiveness of the second BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 booster vaccine dose (ie, fourth inoculation) is well established, but its safety has yet to be fully understood. The absence of sufficient vaccine safety information is one of the key contributors to vaccine hesitancy. In this study, we aimed to evaluate the safety profile of the second BNT162b2 mRNA COVID-19 booster vaccine using data from a retrospective cohort and a prospective cohort.
METHODS: To evaluate the safety profile of the second booster vaccine, we analysed its short-term effects and compared them to those of the first booster by using data from, first, a retrospective cohort of 250 000 random members of the second-largest health-care organisation in Israel (Maccabi Healthcare Services) and, second, a prospective cohort (the PerMed study) of 4698 participants from all across Israel. Individuals who were aged 18 years or older who received the second BNT162b2 mRNA COVID-19 vaccine booster during the vaccination campaign, from Dec 30, 2021, to July 22, 2022, were eligible for inclusion in the retrospective cohort analysis. To be included in the PerMed study, participants needed to be 18 years or older, members of Maccabi Healthcare Services at the time of enrolment, using their own smartphone, and be able to give informed consent by themselves. Participants from the prospective cohort received smartwatches, downloaded a dedicated mobile application, and granted access to their medical records. The smartwatches continuously monitored several physiological measures, including heart rate. For analysis of the prospective cohort data, we used the Kruskal-Wallis test to compare heart rate levels observed before and after vaccination. The mobile application collected daily self-reported questionnaires on local and systemic reactions. Medical records of the retrospective cohort were accessed to examine the occurrence of 25 potential adverse events, and we evaluated the risk differences between 42 days in the periods before and after vaccination in a pairwise method using non-parametric percentile bootstrap.
FINDINGS: The retrospective cohort included 94 169 participants who received the first booster and 17 814 who received the second booster. Comparing the 42 days before and after vaccination, the second booster was not associated with any of the 25 adverse events investigated, including myocardial infarction (risk difference, 2·25 events per 10 000 individuals [95% CI -3·93 to 8·98]) and Bell's Palsy (-1·68 events [-5·61 to 2·25]). None of the individuals was diagnosed with myocarditis or pericarditis following vaccination with the second booster. The prospective cohort included 1785 participants who received the first booster and 699 who received the second booster. We found no significant differences after inoculation with the first booster compared with the second booster (heart rate: day 2 [p=0·3], day 6 [p=0·89]; extent of self-reported reactions [p=0·06]). We found a significant increase in mean heart rate relative to that observed during the week before vaccination (baseline) levels during the first 3 days following the second booster (p<0·0001), peaking on day 2 (mean difference of 1·61 bpm [1·07 to 2·16] compared with baseline). Mean heart rate values returned to baseline levels by day 6 (-0·055 bpm [-0·56 to 0·45] compared with baseline).
INTERPRETATION: Both our retrospective and prospective analyses support the safety of the second booster, with our findings reflecting physicians' diagnoses, patients' objective physiological measures, and patients' subjective reactions. We believe this study provides safety assurances to the global population who are eligible to receive an additional COVID-19 booster inoculation. These assurances can help increase the number of high-risk individuals who opt to receive this booster vaccine and thereby prevent severe outcomes associated with COVID-19.
FUNDING: European Research Council (ERC).
参考来源
- Yechezkel M, Mofaz M, Painsky A, et al. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study. Lancet Respir Med. 2022. PMID: 36410364. doi:10.1016/S2213-2600(22)00407-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。